Designing and Testing Broadly-Protective Filoviral Vaccines Optimized for Cytotoxic T-Lymphocyte Epitope Coverage

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Fenimore, Paul W ^a   Muhammad, Majidat A ^b   Fischer, William M ^a   Foley, Brian T ^a   Bakken, Russell R ^b   Thurmond, James R ^c   Yusim, Karina ^a   Yoon, Hyejin ^a   Parker, Michael ^b   Hart, Mary Kate ^d   Dye, John M ^b   Korber, Bette ^a   Kuiken, Carla ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c INDIANA UNIVERSITY   (United States)

^d DynPort Vaccine Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FILOVIRUS VACCINE; IMMUNOGLOBULIN G; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DRUG DESIGN; EBOLA VIRUS; FEMALE; FILOVIRUS; FILOVIRUS INFECTION; GENETIC VARIABILITY; IMMUNOGENICITY; IN VIVO STUDY; MARBURG VIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SPECIES DIFFERENCE; STRAIN DIFFERENCE; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; COMPUTATIONAL BIOLOGY; CROSS REACTIONS; DRUG DESIGN; EBOLA VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; HEPACIVIRUS; HUMANS; MICE; MICE, INBRED C57BL; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL HEPATITIS VACCINES; VIRAL PROTEINS; VIRAL VACCINES;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MARBURGVIRUS;

EID: 84867045694     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044769     Document Type: Article

References (34)

1. Siegert R, (1987) [Marburg, Lassa and Ebola virus as cause of hemorrhagic fever.] Dtsch. Med. Wochenschr. 103: 1176-1181.
2. Leroy EM, Rouquet P, Formenty P, Souquière S, Kilbourne A, et al. (2004) Multiple Ebolavirus transmission events and rapid decline of Central African wildlife, Science. 303: 387-390.
3. Kuhn JH (2008) Filoviruses: A Compendium of 40 Years of Epidemiological, Clinical, and Laboratory Studies. Springer-Verlag/Wien.
4. Barrette R, Metwally S, Rowland J, Xu L, Zaki S, et al. (2009) Discovery of swine as a host for the Reston Ebolavirus, Science. 325: 204-206.
5. Cohen J, Powderly WG (2004) Infectious Diseases, 2nd Edition. Mosby; 2004, 2106-2107.
6. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. (2007) Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nature Medicine 13: 100-106.
7. Kunh JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, et al. (2010) Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations, Arch. Virol. 155; 2083-2103.
8. Miranda ME, White ME, Dayrit MM, Hayes CG; Ksiazek TG, et al. (1991) Seroepidemiological study of filovirus related to Ebola in the Philippines, Lancet. 337: 425-426.
9. Towner JS, Sealy TK, Khristova ML, Albariño CG, Conlan S, et al. (2008) Newly discovered Ebolavirus associated with hemorrhagic fever outbreak in Uganda, PLoS Pathogens. 4: e1000212.
10. Negredo A, Palacios G, Vázquez-Morón S, González F, Dopazo H, et al. (2011) Discovery of an ebolavirus-like filovirus in europe, PLoS Pathog. 7: e1002304.
11. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, et al. (2005) Fruit bats as reservoirs of Ebolavirus. Nature 438: 575-576.
12. Towner JS, Pourrut X, Albariño C, Nkogue C, Bird B, et al. (2007) Marburgvirus infection detected in a common African bat, PLoS One. 2: e764.
13. Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, et al. (2010) Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog 6: e1000904.
14. Korber BT, Letvin NL, Haynes BF, (2009) T-cell vaccine strategies for Human Immunodeficiency Virus, the virus with a thousand faces. J. Virology 83: 8300-8314.
15. Santra S, Liao HX, Zhang R, Muldoon M, Watson S, et al. (2010) Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 16: 324-8.
16. Kong W-P, Wu L, Wallstrom TC, Fischer W, Yang Z-Y, et al. (2009) Expanded breadth of the T-cell response to mosaic human immunodeficiency Virus Type 1 Enveloped DNA vaccination. J. Virology 83: 2201-2215.
17. Xu L, Sanchez A, Yang Z-Y, Zaki SR, Nabel EG, et al. (1998) Immunization for Ebolavirus infection, Nature Medicine. 4: 37-42.
18. Olinger GG, Bailey MA, Dye JM, Bakken R, Kuehne A, et al. (2005) Protective cytotoxic T-cell responses induced by Venezuelan equine encephalitis virus replicons expressing Ebolavirus proteins. J. Virology 79: 14189-14196.
19. Wilson JA, Hart MK, (2001) Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein, J. Virol. 75: 2660-2664.
20. Hart MK, Olinger GG, Bailey MA (2005) Immunogenic compositions and vaccines for Ebola. United State Patent Application 20100034843.
21. Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, et al. (2011) CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 17: 1128-31.
22. Sullivan NJ, Martin JE, Graham BS, Nabel GJ, (2009) Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7: 393-400.
23. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez A, et al. (2004) Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J. Virology 78: 10370-10377.
24. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, et al. (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune response in rhesus monkeys. Nature Medicine 16: 319-323.
25. Santra S, Muldoon M, Watson S, Buzby A, Balachandran H, et al. Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 428: 121-127.
26. Ndhlovu ZM, Piechocka-Trocha A, Vine S, McMullen A, Koofhethile KC, et al. (2011) Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-Specific CD8+ T cells. J. Immunol. 186: 6914-6924.
27. Yusim K, Fischer W, Yoon H, Thurmond J, Fenimore PW, et al. (2010) Genotype 1 and global hepatitis C T-cell vaccine designed to optimize coverage of genetic diversity. J. Gen. Virol. 91: 1194-1206.
28. Guindon S, Gascuel O, (2003) A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Systematic Biology 52: 696-704.
29. Bruno WJ, (1996) Modeling residue usage in aligned protein sequences via maximum likelihood. Molecular Biology and Evolution 13: 1368-1374.
30. Price MN, Dehal PS, Arkin AP, (2010) FastTree 2 - Approximately Maximum-Likelihood Trees for Large Alignments. PLoS ONE 5: e9490.
31. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J, (1998) A Mouse Model for Evaluation of Prophylaxis and Therapy of Ebola Hemorrhagic. Fever. J. Infect. Diseases 178: 651-661.
32. National Research Council (1996) Guide for the Care and Use of Laboratory Animals. Washington: National Academy Press. 124 p.
33. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, et al. (2000) Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine (19) (): 142-53.
34. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, et al. (2000) Epitopes involved in antibody-mediated protection from Ebola virus. Science 287: 1664-1666.